RxDoctor Payments Data

Nicole Duncan, APRN

Psychiatric/Mental Health · Hollywood, FLNPI 1891452306

Payments from drug & device makers

$2,826in general payments, 2019–2025

Across 87 payments — averaging $32.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$682
  • Alkermes, Inc.$461
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$207
  • Otsuka America Pharmaceutical, Inc.$165
  • E.r. Squibb & Sons, L.L.C.$122
  • plus $162 from 3 others

What the payments were for

  • Food & beverage$2,814100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,826 in reported general payments places this provider in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$4,349
Medicare patients
35
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate62$204,905
VraylarCariprazine Hcl16$23,178
RexultiBrexpiprazole14$20,010
TrintellixVortioxetine Hydrobromide24$13,096
Aripiprazole68$7,710
Clozapine23$2,729
Fluphenazine Hcl13$1,686
Bupropion XlBupropion Hcl47$1,612
Clomipramine Hcl12$1,241
Trazodone Hcl118$1,084
Benztropine Mesylate85$938
Olanzapine36$929
Quetiapine Fumarate76$809
Duloxetine Hcl28$740
Haloperidol20$697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$81$204,90562 claims
Otsuka America Pharmaceutical, Inc.Rexulti$165$20,01014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →